Quality of Life in Lymphoma Patients One Year Post-chemotherapy

Recruiting

• Conditions: Lymphoma
• Interventions: Other: Quality of life

• Registration Number: NCT04187118
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in "after cancer period". Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.

Detailed Description

Quality of life, as well anxiety, depression, social isolation, fear of cancer recurrence, post traumatic stress, will be measured in lymphoma patients, after a first line chemotherapy. Care cancer pathway will be also evaluated. Self-administered questionnaires will be performed on website (www.hospitalidee.fr) after inclusion and 12 months after.

Study Timeline

• Study First Submitted: 2019-11-27
• Study First Submitted QC: 2019-12-03
• Study First Posted: 2019-12-05
• Study Start: 2020-01-28
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-18
• Last Update Posted: 2023-09-21
• Primary Completion: 2025-06-01
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Patients being in complete response after a first therapy for lymphoma
• Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation
• Patients informed of the study and not opposed to the research

Exclusion Criteria

• Patients under legal guardian .
• Patients unavailable to formulate non-opposition to the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lymphoma patients	Quality of life	Patients being in complete response after a first therapy for malignant lymphoma.

Primary Outcome Measures

Name	Time	Method
Quality of life change: Quality of Life-C30 French version	Change from baseline quality of life at 12 month	Health-related quality of life is evaluated by the use of Quality of Life-C30 French version

Trial Locations

Locations (1)

University Hospital Toulouse; 🇫🇷 Toulouse, France